5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells

Human Gene Therapy

Volumn 22, Issue 3, 2011, Pages 283-292

  He, Xiaoping ^a   Liu, Jia ^a   Yang, Chunyan ^b   Su, Changqing ^a   Zhou, Chengliang ^b   Zhang, Qi ^a   Li, Linfang ^a   Wu, Hongping ^a   Liu, Xinyuan ^b   Wu, Mengchao ^a   Qian, Qijun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 35 FIBER PROTEIN; ADENOVIRUS VECTOR; COMPLEMENTARY DNA; HYBRID PROTEIN; MUSCLE PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD46; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; RECEPTORS, VIRUS; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 79952668651     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.058     Document Type: Article

References (31)

1. Auer, D., Reimer, D., Porto, V., et al. (2009). Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer. Breast Cancer Res. Treat. 116, 103-111.
2. Bergelson, J.M., Cunningham, J.A., Droguett, G., et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323. (Pubitemid 27114163)
3. Brouwer, E., Havenga, M.J., Ophorst, O., et al. (2007). Human adenovirus type 35 vector for gene therapy of brain cancer: Improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther. 14, 211-219. (Pubitemid 46106964)
4. Chen, J., Su, C., Lu, Q., et al. (2008). Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey. Mol. Cancer Ther. 7, 1562-1568.
5. Gaggar, A., Shayakhmetov, D.M., and Lieber, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412. (Pubitemid 37466191)
6. Ganesh, S., Gonzalez Edick, M., Idamakanti, N., et al. (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 67, 4399-4407. (Pubitemid 46815089)
7. Hoffmann, D., Heim, A., Nettelbeck, D.M., et al. (2007a). Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum. Gene Ther. 18, 51-62. (Pubitemid 46105464)
8. Hoffmann, D., Meyer, B., and Wildner, O. (2007b). Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J. Gene Med. 9, 764-778. (Pubitemid 47386861)
9. Iacobelli-Martinez, M., Nepomuceno, R.R., Connolly, J., and Nemerow, G.R. (2005). CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cyto-kines. J. Virol. 79, 11259-11268. (Pubitemid 41170668)
10. Jiang, M., Shi, W., Zhang, Q., et al. (2006). Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin. Cancer Res. 12, 6179-6185. (Pubitemid 44703784)
11. Jin, J., Liu, H., Yang, C., et al. (2009). Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: In vitro and in vivo evaluation. Mol. Cancer Ther. 8, 1387-1397.
12. Kawakami, Y., Li, H., Lam, J.T., et al. (2003). Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res. 63, 1262-1269. (Pubitemid 36348704)
13. Li, Y.M., Song, S.T., Jiang, Z.F., et al. (2008). Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. World J. Gastroenterol. 14, 1274-1279.
14. Liu, X.Y. (2006). Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 16, 879-886. (Pubitemid 44764197)
15. Lu, Z.Z., Ni, F., Hu, Z.B., et al. (2006). Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp. Hematol. 34, 1171-1182.
16. Ma, L., Liu, J., Shen, J., et al. (2010). Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol. Ther. 9, 554-561.
17. Nemunaitis, J., Senzer, N., Sarmiento, S., et al. (2007). A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther. 14, 885-893. (Pubitemid 47557221)
18. Opyrchal, M., Aderca, I., and Galanis, E. (2009). Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol. Biol. 542, 705-717.
19. Ranki, T., Kanerva, A., Ristimaki, A., et al. (2007). A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther. 14, 58-67. (Pubitemid 44942866)
20. Rein, D.T., Breidenbach, M., Kirby, T.O., et al. (2005). A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin. Cancer Res. 11, 1327-1335. (Pubitemid 40175787)
21. Shayakhmetov, D.M., Li, Z.Y., Ni, S., and Lieber, A. (2002). Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 62, 1063-1068. (Pubitemid 34160288)
22. Stoff-Khalili, M.A., Rivera, A.A., Stoff, A., et al. (2007). Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. Int. J. Cancer 120, 935-941. (Pubitemid 46175417)
23. Stoff-Khalili, M.A., Stoff, A., Rivera, A.A., et al. (2005). Gene transfer to carcinoma of the breast with fiber-modified ade-noviral vectors in a tissue slice model system. Cancer Biol. Ther. 4, 1203-1210.
24. Su, C., Na, M., Chen, J., et al. (2008). Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with anti-angiogenesis gene for increased efficacy. Mol. Cancer Res. 6, 568-575. (Pubitemid 351521838)
25. Su, C., Peng, L., Sham, J., et al. (2006). Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 13, 918-927.
26. Wang, G., Li, G., Liu, H., et al. (2009). E1B 55-kDa deleted, Ad5/ F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J. Gene Med. 11, 477-485.
27. Wang, X., Su, C., Cao, H., et al. (2008). A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent anti-tumor efficacy on common human solid cancers. Mol. Cancer Ther. 7, 1598-1603.
28. Yu, L., Shimozato, O., Li, Q., et al. (2007). Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its in-fectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 27, 2311-2316. (Pubitemid 47228069)
29. Yu, L., Takenobu, H., Shimozato, O., et al. (2005). Increased in-fectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol. Rep. 14, 831-835.
30. Zhang, Q., Nie, M., Sham, J., et al. (2004). Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res. 64, 5390-5397. (Pubitemid 39006561)
31. Zou, W., Luo, C., Zhang, Z., et al. (2004). A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23, 457-464. (Pubitemid 38175000)